>I assume part of your argument is commentary in favor of mnta.<
It could be interpreted that way :- )
>We know mnta has characterized and filed on lovenox and copaxone. But we don't know what else mnta is on a filing track for, if anything.<
We do know (assuming Craig Wheeler can be trusted) that the bulk of MNTA’s R&D has shifted to glycoproteins. However, no FoB program can be on a full-fledged filing track until the law specifies a framework for FoB filings.
#msg-25514154 contains some informed speculation about which FoB programs MNTA might be working on.
Market Data 
Markets 
AI
